Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Impact of geographic disparity on liver allocation for hepatocellular cancer in the United States.

Kadry Z, Schaefer EW, Uemura T, Shah AR, Schreibman I, Riley TR 3rd.

J Hepatol. 2012 Mar;56(3):618-25. doi: 10.1016/j.jhep.2011.08.019. Epub 2011 Oct 23.

PMID:
22027581
2.

Liver transplantation for hepatocellular carcinoma: the MELD impact.

Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH.

Liver Transpl. 2004 Jan;10(1):36-41.

3.

Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.

Schmitt TM, Kumer SC, Shah N, Argo CK, Northup PG.

Ann Hepatol. 2010 Oct-Dec;9(4):390-6.

PMID:
21057157
4.

Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation.

Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V.

Am J Transplant. 2006 Aug;6(8):1957-62. Epub 2006 Jun 9.

5.

Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.

Schlansky B, Chen Y, Scott DL, Austin D, Naugler WE.

Liver Transpl. 2014 Sep;20(9):1045-56. doi: 10.1002/lt.23917. Epub 2014 Aug 4.

6.

Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.

Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G, Cristina Morelli M, Ravaioli M, Daniele Pinna A.

Liver Transpl. 2011 Nov;17(11):1344-54. doi: 10.1002/lt.22397.

7.

Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.

Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM.

Dig Dis Sci. 2012 Mar;57(3):806-12. doi: 10.1007/s10620-011-1910-9. Epub 2011 Sep 28.

8.

Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.

Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box T.

Liver Transpl. 2012 Apr;18(4):423-33. doi: 10.1002/lt.23385.

9.

Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment.

Halazun KJ, Patzer RE, Rana AA, Verna EC, Griesemer AD, Parsons RF, Samstein B, Guarrera JV, Kato T, Brown RS Jr, Emond JC.

Hepatology. 2014 Dec;60(6):1957-62. doi: 10.1002/hep.27272. Epub 2014 Sep 10.

PMID:
24954365
10.

An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data.

Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, Magee JC, Lok AS, Fontana RJ, Marrero JA.

Liver Transpl. 2009 Aug;15(8):859-68. doi: 10.1002/lt.21778.

11.

Liver transplantation for hepatocellular carcinoma in Singapore.

Wai CT, Lee YM, Wang SC, Da Costa M, Isaac J, Wee A, Lim SG.

Singapore Med J. 2006 Jul;47(7):584-7.

12.

Liver transplantation for hepatocellular carcinoma: defining the impact of using extended criteria liver allografts.

Facciuto ME, Singh MK, Katta U, Samaniego S, Sharma J, Rodriguez-Davalos M, Sheiner P, Kim-Schluger L, Wolf DC.

Transplantation. 2011 Aug 27;92(4):446-52. doi: 10.1097/TP.0b013e3182252733.

PMID:
21694662
13.

The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.

Patel MS, Kohn R, Kratz JR, Shah JA, Markmann JF, Vagefi PA.

J Am Coll Surg. 2015 Jun;220(6):1001-7. doi: 10.1016/j.jamcollsurg.2014.12.050. Epub 2015 Jan 21.

PMID:
25868408
14.
15.

Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Washburn K, Edwards E, Harper A, Freeman R.

Am J Transplant. 2010 Jul;10(7):1643-8. doi: 10.1111/j.1600-6143.2010.03127.x. Epub 2010 May 10.

16.

Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.

Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A, Garrigan K, Terella A, Hertl M, Cosimi AB, Chung RT.

Liver Transpl. 2004 Nov;10(11):1343-54.

17.

Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients.

Gaba RC, Kallwitz ER, Parvinian A, Bui JT, Von Roenn NM, Berkes JL, Cotler SJ.

Ann Hepatol. 2013 Sep-Oct;12(5):766-73.

18.

A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.

Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, Morel P, Mentha G, Combescure C.

Hepatology. 2012 Jul;56(1):149-56. doi: 10.1002/hep.25603. Epub 2012 Jun 18.

PMID:
22271250
19.

Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time.

Decaens T, Roudot-Thoraval F, Hadni-Bresson S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Sulpice L, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouilleres O, Cherqui D, Duvoux C.

Liver Transpl. 2006 Dec;12(12):1761-9.

20.

A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.

Piscaglia F, Camaggi V, Ravaioli M, Grazi GL, Zanello M, Leoni S, Ballardini G, Cavrini G, Pinna AD, Bolondi L.

Liver Transpl. 2007 Jun;13(6):857-66.

Supplemental Content

Support Center